公开(公告)号：US10189836B2

公开(公告)日：2019-01-29

申请号：US16009596

申请日：2018-06-15

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Rongbao Hua ,  Terry Kellar ,  Wei Li ,  Paul Gibbons ,  Mark Edward Zak

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20180354959A1

公开(公告)日：2018-12-13

申请号：US16104347

申请日：2018-08-17

Applicant: Genentech, Inc.

Inventor： Mark Zak ,  Terry Kellar ,  Paul Gibbons

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds of Formula (I): salts thereof and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US10131675B2

公开(公告)日：2018-11-20

申请号：US15699095

申请日：2017-09-08

Applicant: Genentech, Inc.

Inventor： Anthony Estrada ,  Snahel Patel ,  Terry Kellar ,  Malcolm Huestis ,  Daniel Shore ,  Michael Siu

IPC: C07D498/14 ,  C07D491/14 ,  C07D519/00 ,  A61K31/5383 ,  A61K45/06 ,  A61K31/553

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

公开(公告)号：US20170145020A1

公开(公告)日：2017-05-25

申请号：US15424536

申请日：2017-02-03

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-Wei Yuen

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61P11/06 ,  C07D403/14 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.